Non-invasive management of infants with SFTPC pathogenic variants
Deborah R Liptzin MD MS1*, Matthew D. McGraw,
MD2, Timothy Stidham, MD3, Jennifer
A. Wambach, MD, MS4, Robin R. Deterding,
MD1
1Department of Pediatrics, Section of Pulmonary and
Sleep Medicine, University of Colorado, Aurora, CO;2Department of Pediatrics, Division of Pulmonology,
University of Rochester Medical Center, Rochester, NY;3Department of Pediatrics, Division of Pediatric
Critical Care, Logan Health Medical Center, Kalispell, MT;4Edward Mallinckrodt Department of Pediatrics,
Washington University School of Medicine and St. Louis Children’s
Hospital, St. Louis, MO.
Funding Sources: DRL has funding from the National Institute of Health
UG1OD024952. MDM reports grant support from the National Institute of
Environmental Health Sciences (NIEHS) P30ES001247, K08ES033290, and
Boehringer Ingelheim (BI) as a scientific advisory committee member for
childhood interstitial lung disease. JAW reports grant support from the
National Heart, Lung and Blood Institute (R01 HL149853, U01 HL134745)
and the Children’s Discovery Institute. TS reports no funding or
conflicts of interest. RRD reports the following:
-Now Vitals, CEO and Founder
-Boehringer Ingelheim, Consultant and Coordinating Investigator
-Earables, Founder and Chief Medical Officer
-EvoEndo, Consultant and Founder
-Roche, Inc., Consultant
-The France Foundation, Consultant
*Corresponding Author: Deborah R Liptzin, dliptzin@yahoo.com